Tus%2525252525252525252525252525252525252525252525252525252525252525252525252525252520qd

# Tus%2525252525252525252525252525252525252525252525252525252525252525252525252525252520qd ## Overview Tus%2525252525252525252525252525252525252525252525252525252525252525252525252525252520qd is a combination product containing hydrocodone bitartrate and chlorpheniramine maleate. Hydrocodone is an opioid antitussive, and chlorpheniramine is a first-generation antihistamine. ## Primary Indications * Symptomatic relief of cough and runny nose associated with allergies or the common cold. ## Adult Dosing * **Tus%2525252525252525252525252525252525252525252525252525252525252525252525252525252520qd Syrup:** 5 mL to 10 mL every 4 to 6 hours as needed. * **Tus%2525252525252525252525252525252525252525252525252525252525252525252525252525252520qd Tablets:** 1 tablet every 4 to 6 hours as needed. * **Maximum Dose:** Do not exceed 6 doses in 24 hours. The exact maximum hydrocodone dose is not specified but should be guided by clinical response and opioid safety guidelines. ## Pediatric Dosing Dosing for children under 12 years of age is not established and not recommended due to the risk of respiratory depression and other serious adverse effects associated with hydrocodone in this population. ## Dose Adjustments * **Hepatic Impairment:** Use with caution. Dose reduction may be necessary. * **Renal Impairment:** Use with caution. Dose reduction may be necessary. ## Contraindications * Hypersensitivity to hydrocodone, chlorpheniramine, or any component of the formulation. * Acute or severe asthma or other respiratory depression. * Gastrointestinal obstruction or paralytic ileus. * Concurrent use with MAO inhibitors or within 14 days of discontinuing MAO inhibitors. * Children under 12 years of age. ## Adverse Effects * **Common:** Drowsiness, dizziness, dry mouth, constipation, nausea, vomiting, blurred vision, confusion. * **Serious:** Respiratory depression, severe hypotension, addiction, tolerance, withdrawal symptoms, seizures, paradoxical excitation, anticholinergic effects (urinary retention, blurred vision, constipation). ## Key Drug Interactions * **CNS Depressants (e.g., alcohol, benzodiazepines, sedatives, other opioids):** Increased risk of sedation, respiratory depression, and profound CNS depression. * **MAO Inhibitors:** May potentiate effects of opioids and antihistamines; may cause severe CNS depression, hypertensive crisis, or respiratory depression. * **CYP3A4 Inhibitors (e.g., macrolide antibiotics, azole antifungals):** May increase hydrocodone plasma concentrations, leading to increased risk of adverse effects. * **Anticholinergic Agents:** Additive anticholinergic effects. ## Monitoring * Respiratory rate and depth. * Level of consciousness and sedation. * Signs of constipation and urinary retention. * Signs of potential abuse or addiction. * Response to therapy. ## Clinical Pearls * This medication carries a risk of opioid misuse, abuse, and addiction. Prescribe only for the shortest duration necessary. * Advise patients to avoid alcohol and other CNS depressants while taking this medication. * Drowsiness is a common side effect; caution patients about operating machinery or driving. * For cough and cold symptoms, consider non-opioid alternatives or symptomatic treatment when possible. *** *This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and product monographs before making clinical decisions. The specific details of drug use may vary based on local protocols and individual patient factors.*